Special considerations in GI bleeding in VWD patients

Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):624-630. doi: 10.1182/hematology.2022000390.

Abstract

Gastrointestinal (GI) bleeding is an important cause of morbidity and mortality in von Willebrand disease (VWD). It has been noted that GI bleeding caused by angiodysplasia is overrepresented in VWD patients compared to other causes. The bleeding from angiodysplasia is notoriously difficult to treat; recurrences and rebleeds are common. A growing body of basic science evidence demonstrates that von Willebrand factor negatively regulates angiogenesis through multiple pathways. VWD is clinically highly associated with angiodysplasia. The predisposition to angiodysplasia likely accounts for many of the clinical difficulties related to managing GI bleeding in VWD patients. Diagnosis and treatment are challenging with the current tools available, and much further research is needed to further optimize care for these patients with regard to acute treatment, prophylaxis, and adjunctive therapies. In this review we provide an overview of the available literature on GI bleeding in VWD and explore the molecular underpinnings of angiodysplasia-related GI bleeding. Considerations for diagnostic effectiveness are discussed, as well as the natural history and recurrence of these lesions and which therapeutic options are available for acute and prophylactic management.

Publication types

  • Review

MeSH terms

  • Angiodysplasia* / complications
  • Angiodysplasia* / diagnosis
  • Angiodysplasia* / therapy
  • Gastrointestinal Hemorrhage / diagnosis
  • Gastrointestinal Hemorrhage / etiology
  • Gastrointestinal Hemorrhage / therapy
  • Humans
  • von Willebrand Diseases* / complications
  • von Willebrand Diseases* / diagnosis
  • von Willebrand Diseases* / therapy
  • von Willebrand Factor / metabolism
  • von Willebrand Factor / therapeutic use

Substances

  • von Willebrand Factor